echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > NEJM: Vinetola combined with aza cytoside to treat acute myeloid leukemia in old age.

    NEJM: Vinetola combined with aza cytoside to treat acute myeloid leukemia in old age.

    • Last Update: 2020-09-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Most patients with acute myeloid leukemia (AML) in old age have poor prognostication, and even if the patient receives the treatment of the normylation agent, it is difficult to achieve satisfactory clinical results.
    previous Phase 1b study, Venetolax combined azacine had a good effect on older AML patients.
    Recently, researchers recruited previously untreated AML patients to conduct Phase III studies, in which patients aged 75 years or older were randomly given Venetura (400mg) or placebo once a day on the basis of standard Azathroside therapy (subderrone or intravenous injections, 75 mg per square metre of surface area, 1 cycle every 28 days, 1-7 days per cycle).
    end point of the study is total survival.
    431 patients, with an average age of 76, included 286 in the Vinetola group and 145 in the placebo group.
    the 20.5-month mid-follow-up, the total survival of the Vinetola group was 14.7 months and that of the control group was 9.6 months (death risk ratio was 0.661). the total remission rate in the
    Venetola group was higher than in the control group (36.7% vs 17.9%), and the compound remission rate (complete or complete remission accompanied by incomplete hematological recovery) was higher than in the control group (66.4% vs 28.3%). the occurrence of major adverse events (including nausea) in the total survival difference of
    was 44%, in the control group it was 35%, the rate of plateboard reduction at level 3 or higher was 45% and 38% respectively, the occurrence of neural granulocytic reduction was 42% and 28%, and the rate of febrile neural cell reduction was 42% and 19%, respectively.
    85 percent of patients in the Venetura group had an infection, compared with 67 percent in the control group, 83 percent in the Vinetura group and 73 percent in the placebo group.
    studies have concluded that Vinetola combined azadenosine can effectively prolong the survival of elderly patients with acute myeloid leukemia aged 75 years and older.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.